DYAI vs. OKYO, QNCX, CYTH, INAB, SABS, ESLA, ACHL, TARA, INKT, and SRZN
Should you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include OKYO Pharma (OKYO), Quince Therapeutics (QNCX), Cyclo Therapeutics (CYTH), IN8bio (INAB), SAB Biotherapeutics (SABS), Estrella Immunopharma (ESLA), Achilles Therapeutics (ACHL), Protara Therapeutics (TARA), MiNK Therapeutics (INKT), and Surrozen (SRZN). These companies are all part of the "biological products, except diagnostic" industry.
OKYO Pharma (NASDAQ:OKYO) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.
OKYO Pharma has a net margin of 0.00% compared to OKYO Pharma's net margin of -234.39%. Dyadic International's return on equity of 0.00% beat OKYO Pharma's return on equity.
Dyadic International received 154 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 63.97% of users gave Dyadic International an outperform vote.
Dyadic International has higher revenue and earnings than OKYO Pharma.
3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Comparatively, 28.8% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
OKYO Pharma currently has a consensus target price of $7.00, indicating a potential upside of 372.97%. Dyadic International has a consensus target price of $6.00, indicating a potential upside of 292.16%. Given Dyadic International's higher probable upside, research analysts clearly believe OKYO Pharma is more favorable than Dyadic International.
In the previous week, Dyadic International had 2 more articles in the media than OKYO Pharma. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.47 beat Dyadic International's score of 0.22 indicating that Dyadic International is being referred to more favorably in the news media.
OKYO Pharma has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
Summary
Dyadic International beats OKYO Pharma on 7 of the 13 factors compared between the two stocks.
Get Dyadic International News Delivered to You Automatically
Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dyadic International Competitors List
Related Companies and Tools
